Publikationen von Marc Hein

van Heuvel, Y.; Schatz, S.; Hein, M.; Dogra, T.; Kazenmaier, D.; Tschorn, N.; Genzel, Y.; Stitz, J.: Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactors. Frontiers in Bioengineering and Biotechnology 11, 1076524 (2023)

Hein, M.; Chawla, A.; Arora , P.; Cattaneo, M.; Winkler, M.; Pöhlmann, S.; Schughart, K.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting. Vaccine Technology VIII, Sitges (Spain) (2022)

Hein, M.; Dogra, T.; Arora , P.; Rand , U.; Genzel, Y.; Cattaneo, M.; Winkler, M.; Cicin-Sain, L.; Bruder, D.; Schughart, K. et al.; Pöhlmann, S.; Kupke, S. Y.; Reichl, U.: Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Hein, M.; Chawla, A.; Arora , P.; Cattaneo, M.; Winkler, M.; Pöhlmann, S.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: Production of influenza A virus-derived defective interfering particles for antiviral therapy in a high cell density perfusion cultivation. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Kupke, S. Y.; Hein, M.; Bdeir, N.; Rand, U.; Marichal-Gallardo, P.; Cicin-Sain, L.; Bruder, D.; Pöhlmann, S.; Schughart, K.; Reichl, U.: Influenza A Virus Defective Interfering Particles for Antiviral Treatment of the Influenza Disease and COVID-19. Vaccine Technology VIII, Sitges (Spain) (2022)

Hein, M.: Producing a new class of defective interfering particles as antiviral. 26th ESACT Meeting, Kopenhagen, Denmark (2019)

Hein, M.: Production of a novel class of influenza A virus-derived defective interfering particle as an antiviral agent. 14th PEACe, Rhode Island, USA (2019)

Hein, M.: Cell culture-based production of influenza A virus-derived defective interfering particles. Dissertation, Otto-von-Guericke-Universität, Magdeburg (2022)